sitaxsentan (Thelin) + sitaxsentan (Thelin) + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cardiac Surgery Subjects

Conditions

Cardiac Surgery Subjects, Subjects Undergoing CABG and/or Cardiac Valve Replacement

Trial Timeline

Aug 10, 2006 → Mar 31, 2008

NCT ID

NCT00838383

About sitaxsentan (Thelin) + sitaxsentan (Thelin) + Placebo

sitaxsentan (Thelin) + sitaxsentan (Thelin) + Placebo is a phase 2 stage product being developed by Pfizer for Cardiac Surgery Subjects. The current trial status is completed. This product is registered under clinical trial identifier NCT00838383. Target conditions include Cardiac Surgery Subjects, Subjects Undergoing CABG and/or Cardiac Valve Replacement.

What happened to similar drugs?

5 of 15 similar drugs in Cardiac Surgery Subjects were approved

Approved (5) Terminated (3) Active (8)

✅Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirinMerckApproved

✅Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + SteroidsNovartisApproved

✅Everolimus + Mycophenolate mofetil + EverolimusNovartisApproved

✅EpinephrinePfizerApproved

✅Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)Mochida PharmaceuticalApproved

🔄Edoxaban + Standard of Care (SOC)Daiichi SankyoPhase 3

🔄Everolimus (RAD001)NovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00838383	Phase 2	Completed	Aug 10, 2006	Mar 31, 2008	Cardiac Surgery Subjects

Competing Products

20 competing products in Cardiac Surgery Subjects

See all competitors

Product	Company	Stage	Hype Score
Edoxaban + Standard of Care (SOC)	Daiichi Sankyo	Phase 3	40
regadenoson	Astellas Pharma	Pre-clinical	26
Baricitinib (LY3009104) 4 mg	Eli Lilly	Phase 2	42
Current Domperidone + Current proton pump inhibitor (PPI)	Johnson & Johnson	Pre-clinical	26
Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin	Merck	Approved	35
Everolimus (RAD001)	Novartis	Phase 3	40
Deferasirox and Deferoxamine	Novartis	Phase 2	35
Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + Steroids	Novartis	Approved	43
TIN816	Novartis	Phase 2	27
Everolimus + Mycophenolate mofetil + Everolimus	Novartis	Approved	43
Pirfenidone + Placebo	Roche	Phase 2	35
Daclizumab	Roche	Phase 1/2	24
Ranolazine + Placebo	Gilead Sciences	Phase 3	32
Insulin infusion with a goal	Novo Nordisk	Phase 3	40
Epinephrine	Pfizer	Approved	50
Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)	Mochida Pharmaceutical	Approved	43
BMS-986224	Bristol Myers Squibb	Phase 1	29
BMS-986231 + Furosemide + Placebo	Bristol Myers Squibb	Phase 2	35
Balinatunfib + Moxifloxacin + Placebo	Sanofi	Phase 1	36
Sotagliflozin + Placebo	Sanofi	Phase 2	27